John Hainsworth

Summary

Affiliation: Sarah Cannon Cancer Center
Country: USA

Publications

  1. Greco F, Hainsworth J. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset. Clin Genitourin Cancer. 2018;16:e893-e898 pubmed publisher
    ..Papillary carcinoma is more common in this group than in the larger RCC population. Although confirmation from prospective studies is needed, RCC-specific treatment should be considered for this group of patients. ..
  2. request reprint
    Hainsworth J, Burris H, Calvert S, Willcutt N, Scullin D, Bramham J, et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 2001;19:335-9 pubmed
    ..Because gemcitabine has activity against a variety of adenocarcinomas, further evaluation of this agent as part of first-line therapy for patients with carcinoma of unknown primary site is appropriate. ..
  3. request reprint
    Hainsworth J, Sosman J, Spigel D, Edwards D, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005;23:7889-96 pubmed
    ..Additional development of this and other combinations of targeted agents is warranted. ..
  4. Hainsworth J, Spigel D, Clark B, Shipley D, Thompson D, Farley C, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010;16:70-5 pubmed publisher
    ..Gemcitabine/irinotecan is the preferable regimen, due to its favorable toxicity profile. However, the moderate efficacy of both regimens underscores the need for novel treatment approaches in this patient population. ..
  5. Hainsworth J, Spigel D, Burris H, Shipley D, Farley C, Macias Perez I, et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116:2448-54 pubmed publisher
    ..Further development of the regimen as a first-line therapy, or with bevacizumab added, is indicated. ..
  6. Hainsworth J, Spigel D, Thompson D, Murphy P, Lane C, Waterhouse D, et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist. 2009;14:1189-97 pubmed publisher
    ..Empiric treatment with paclitaxel, carboplatin, bevacizumab, and erlotinib is effective and well tolerated as first-line treatment for patients with CUP. Further development of this regimen is warranted. ..
  7. Hainsworth J, Spigel D, Markus T, Shipley D, Thompson D, Rotman R, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma. 2009;9:223-8 pubmed publisher
    ..Definitive demonstration of improved efficacy versus rituximab/chemotherapy alone will require a randomized phase III trial. ..
  8. Hainsworth J, Waterhouse D, Shih K, Boccia R, Priego V, McCleod M, et al. Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). Lung Cancer. 2018;118:6-12 pubmed publisher
    ..Further investigation of the role of neoadjuvant pemetrexed/carboplatin requires a larger, randomized clinical trial. ..
  9. Hainsworth J, Spigel D, Sosman J, Burris H, Farley C, Cucullu H, et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer. 2007;5:427-32 pubmed publisher
    ..The importance of PDGFR inhibition in the treatment of advanced clear cell renal carcinoma remains unclear. Further development of this particular combination is not planned or recommended. ..

More Information

Publications26

  1. Hainsworth J, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol. 2009;36:44-51 pubmed publisher
    ..This review summarizes current recommendations for the evaluation and treatment of patients in each of these favorable prognostic subsets. ..
  2. Spigel D, Hainsworth J, Shipley D, Mekhail T, Zubkus J, Waterhouse D, et al. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. Lung Cancer. 2018;117:38-43 pubmed publisher
    ..Severe myelosuppression was common with this regimen, in spite of prophylactic pegfilgrastim. These results are consistent with those of other trials in showing no role for amrubicin in the first-line treatment of SCLC. ..
  3. request reprint
    Hainsworth J, Shih K, Shepard G, Tillinghast G, Brinker B, Spigel D. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol. 2012;10:240-6 pubmed
    ..Ongoing randomized phase III trials will clarify the role of bevacizumab in this setting. ..
  4. Hainsworth J, Cebotaru C, Kanarev V, Ciuleanu T, Damyanov D, Stella P, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5:1630-6 pubmed publisher
    ..Based on preclinical data and recent clinical observations, further development of AZD6244 in NSCLC should focus on BRAF or RAS mutation-positive patients and/or AZD6244-based combination regimens. ..
  5. Hainsworth J, Spigel D, Greco F, Shipley D, Peyton J, Rubin M, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J. 2011;17:267-72 pubmed publisher
    ..The high level of efficacy suggests that incorporation of these targeted agents into first-line therapy should be further explored. ..
  6. Hainsworth J, Infante J, Spigel D, Arrowsmith E, Boccia R, Burris H. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011;29:451-5 pubmed publisher
    ..Panobinostat was generally well-tolerated. Panobinostat had no activity in this group of patients with refractory renal carcinoma. Further development of panobinostat in renal carcinoma is not recommended. ..
  7. Hainsworth J, Spigel D, Burris H, Waterhouse D, Clark B, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28:2131-6 pubmed publisher
    ..The benefits of this combination regimen, versus sequential use of these two agents, requires further study. ..
  8. Hainsworth J, Ervin T, Friedman E, Priego V, Murphy P, Clark B, et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer. 2010;116:3663-9 pubmed publisher
    ..The administration of angiogenesis inhibitors concurrently with radiotherapy and temozolomide may optimize the opportunity to improve therapy. ..
  9. request reprint
    Hainsworth J. Diagnosis, staging, and clinical characteristics of the patient with mediastinal germ cell carcinoma. Chest Surg Clin N Am. 2002;12:665-72 pubmed
    ..Further details regarding the treatment of mediastinal germ cell tumors are presented elsewhere in this issue. ..
  10. request reprint
    Hainsworth J, Erland J, Barton J, Thompson D, Stagg M, Bradof J, et al. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer. 2003;5:33-8 pubmed
    ..A randomized comparison of this regimen versus single-agent weekly docetaxel is in progress...
  11. request reprint
    Hainsworth J, Mainwaring M, Thomas M, Porter L, Gian V, Jones S, et al. Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients. Clin Lung Cancer. 2003;4:347-55 pubmed
    ..A therapeutic trial of gefitinib should be considered in all patients with refractory NSCLC...
  12. request reprint
    Hainsworth J, Greco F. The role of weekly docetaxel in the treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2002;3 Suppl 2:S17-22 pubmed
    ..Addition of various targeted agents (eg, epidermal growth factor receptor inhibitors, antiangiogenesis agents) also merits evaluation...
  13. Spigel D, Rubin M, Gian V, Shipley D, Burris H, Kosloff R, et al. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer. 2017;113:79-84 pubmed publisher
    ..Both regimens tested had limited efficacy, consistent with results from other studies. ClinicalTrials.gov ID:NCT00609804. ..
  14. request reprint
    Hainsworth J, Spigel D, Raefsky E, Kuzur M, Yost K, Kommor M, et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2005;104:1992-7 pubmed
    ..The current study was performed to evaluate the activity of combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site...
  15. request reprint
    Hainsworth J, Spigel D, Farley C, Thompson D, Shipley D, Greco F. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007;25:1747-52 pubmed
    ..We therefore have evaluated the efficacy and toxicity of this combination in patients with CUP...
  16. request reprint
    Hainsworth J, Spigel D, Litchy S, Greco F. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24:3548-54 pubmed
    ..To evaluate the efficacy of chemotherapy with paclitaxel, carboplatin, and etoposide in advanced adult poorly differentiated neuroendocrine carcinomas...
  17. request reprint
    Hainsworth J, Murphy P, Alemar J, Daniel B, Young R, Yardley D. Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy. Breast Cancer Res Treat. 2016;160:41-49 pubmed
    ..However, HER2-targeted therapy was not effective in such patients. FISH and IHC staining remain the standards for HER2 determination. ..